Table of contents


Research Highlights

Genetics: The crystal ball clears for breast cancer therapy? | PDF (152 KB)

p383 | doi:10.1038/nrclinonc.2011.91

Screening: Bad breath ... scenting victory? | PDF (52 KB)

p384 | doi:10.1038/nrclinonc.2011.80

Targeted therapies: Radiopeptide therapy improves outcomes for neuroendocrine cancers | PDF (115 KB)

p384 | doi:10.1038/nrclinonc.2011.86

Genetics: Melanoma—GRIN and TRAPP it | PDF (57 KB)

p385 | doi:10.1038/nrclinonc.2011.79

Treatment modalities: HIFU is effective for unresectable HCC | PDF (57 KB)

p385 | doi:10.1038/nrclinonc.2011.81

Experimental therapies: I've got you under my skin | PDF (58 KB)

p385 | doi:10.1038/nrclinonc.2011.89

Hematology: Allografting offers better outcomes than autografting for patients with myeloma | PDF (60 KB)

p386 | doi:10.1038/nrclinonc.2011.78

Surgical oncology: Good things don't come to those who watchfully wait | PDF (152 KB)

p386 | doi:10.1038/nrclinonc.2011.84

Top

News and Views

Health services: How can we address cancer care after a natural disaster?

Chiyo K. Imamura & Naoto T. Ueno

p387 | doi:10.1038/nrclinonc.2011.92

On 11 March 2011, a magnitude 9.0 earthquake and subsequent tsunami caused unprecedented devastation in Japan. Over 20,000 people lost their lives or went missing and more than 100,000 people had to evacuate their homes. Many victims are patients with chronic diseases, including cancer, who face interrupted or discontinued therapy.

Combination therapy: New treatment paradigm for locally advanced cervical cancer?

Peter G. Rose

p388 | doi:10.1038/nrclinonc.2011.85

Despite the improved progression-free survival and overall survival demonstrated by cisplatin–gemcitabine chemoradiation in a phase III randomized trial in patients with stage IIB to IVA cervical cancer, the acute and chronic toxic effects urge caution before embracing this as a new treatment paradigm.

Medical oncology: Patients with brain metastases in early-phase trials

Nicholas F. Marko & Robert J. Weil

p390 | doi:10.1038/nrclinonc.2011.73

A recent publication presented objective evidence that patients with and without brain metastases perform similarly in phase I clinical trials for advanced-stage cancer. This finding supports what neurosurgeons and neuro-oncologists have long suspected; namely, that the presence of brain metastases need not mandate exclusion of patients from early-phase clinical trials.

Top

Focus on: metastasis

Reviews

Antiangiogenic therapy, hypoxia, and metastasis: risky liaisons, or not?

Katrien De Bock, Massimiliano Mazzone & Peter Carmeliet

p393 | doi:10.1038/nrclinonc.2011.83

Antiangiogenic therapy is thought to starve tumors by cutting their nutrient and oxygen supply. The authors review evidence for a potential link between hypoxia signaling and an invasive switch that occurs in cancer cells, through which antiangiogenic drugs could increase the risk of tumor metastasis in certain conditions, and discuss approaches to reduce tumor dissemination.

The role of local therapy in the management of lung and liver oligometastases

Simon S. Lo, Susan D. Moffatt-Bruce, Laura A. Dawson, Roderich E. Schwarz, Bin S. Teh, Nina A. Mayr, Jiade J. Lu, John C. Grecula, Thomas E. Olencki & Robert D. Timmerman

p405 | doi:10.1038/nrclinonc.2011.75

The existence of a state of limited metastasis or oligometastasis observed in selected patients is associated with favorable outcomes. This Review discusses the role of local therapy for oligometastases that arise in lung and liver, the challenge of identifying the patients who will benefit from the treatment of their oligometastatic disease and how to select the right local therapy for these patients.

Top

Corrections

Correction: Targeted therapy in non-small-cell lung cancer—is it becoming a reality?

F. Janku, D. J. Stewart & R. Kurzrock

p384 | doi:10.1038/nrclinonc.2011.82

Correction: Hematology in 2010: New therapies and standard of care in oncology

V. T. DeVita Jr & G. P. Canellos

p384 | doi:10.1038/nrclinonc.2011.93

Top

Reviews

Continuing Medical Education

Optimal therapy for acute lymphoblastic leukemia in adolescents and young adults

Eric S. Schafer & Stephen P. Hunger

p417 | doi:10.1038/nrclinonc.2011.77

The survival rate for adolescents and young adults with acute lymphoblastic leukemia has improved over the past decades. However, it is still behind the overall survival of children with this disease. In this Review, Schafer and Hunger analyze recent studies that have shown improved outcomes for adolescents and adults treated with pediatric-based regimens offering a potential solution for the “adolescents and young adults gap”.

BRAF targeted therapy changes the treatment paradigm in melanoma

Antoni Ribas & Keith T. Flaherty

p426 | doi:10.1038/nrclinonc.2011.69

Therapeutic advances in melanoma seem on the horizon, with the identification of BRAF as a principal therapeutic target. The authors describe the scientific basis for the targeting of BRAF mutations in cancer, the early clinical data with BRAF inhibitors, and how combinatorial therapies may address the current limitations of their use in the clinic.

Top

Perspectives

Opinion

Adjuvant chemotherapy in 2011 for patients with soft-tissue sarcoma

Igor Matushansky & Robert N. Taub

p434 | doi:10.1038/nrclinonc.2011.36

Many patients with soft-tissue sarcomas are treated with doxorubicin-based adjuvant chemotherapy, but whether this therapy translates into a survival benefit is controversial. The authors of this Perspectives article critically analyze available clinical data and discuss the implications of these data on current and future treatment efforts.

Opinion

Integrating pharmacogenetics into gemcitabine dosing—time for a change?

Joseph Ciccolini, Cédric Mercier, Laetitia Dahan & Nicolas André

p439 | doi:10.1038/nrclinonc.2011.1

A number of biomarkers that predict clinical outcome in response to gemcitabine treatment have been identified. These markers could be used in the clinic to personalize treatment, thereby improving efficacy and reducing adverse effects. The authors of this article describe how treatment can be tailored according to the pharmacogenetics and pharmacokinetics of each patient. In particular, evaluating the status of the liver enzyme cytidine deaminase holds promise as a strategy to optimize therapy.

Top

Correspondence

Correspondence: P5 medicine: a plus for a personalized approach to oncology

Alessandra Gorini & Gabriella Pravettoni

p444 | doi:10.1038/nrclinonc.2010.227-c1

Correspondence: Too early to say, “no targeting of mitosis!”

Katsumi Kitagawa

p444 | doi:10.1038/nrclinonc.2010.228-c1

Correspondence: (Not) too early to say, “no targeting of mitosis!”

Edina Komlodi-Pasztor, Dan Sackett, Julia Wilkerson & Tito Fojo

p444 | doi:10.1038/nrclinonc.2010.228-c2

Extra navigation

Subscribe

Subscribe to Nature Reviews Clinical Oncology

Advertisement